Lorlatinib in frontline treatment of advanced ALK-positive non-small cell lung cancer: a highly efficient new standard of care but still challenging to manage.

ABSTRACT:

SUBMITTER: Wespiser M 

PROVIDER: S-EPMC11826285 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature